関連する実験動画

Updated: Sep 9, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

炎症抑制性能を向上させるフェノール・アミン触媒コーティングによる酸化窒素放出カテーテル

Qingqing Fan^1,2, Shu Geng¹, Tanveer A Tabish³

¹School of Chemical Engineering and Australian Centre for Nanomedicine (ACN), The University of New South Wales, Sydney, NSW, 2052, Australia.

Advanced healthcare materials

|August 29, 2025

まとめ

この研究では,窒素酸化物 (NO) を放出し,血管機能を強化し,炎症を軽減する新しいナノコーティングを導入しました. タニン酸とセレノシスタミンのコーティングは,持続的なNO放出を提供し,細胞の活性を改善します.

科学分野:

バイオマテリアル科学
ナノテクノロジー
医療機器工学

背景:

窒素酸化物 (NO) は血管拡張,細菌抑制,炎症制御に不可欠です.
現在のNOを放出するカテーターは,持続的な放出と製造の複雑性に制限があります.

研究の目的:

触媒で酸化窒素を生成する新しいナノコーティングを開発し,特徴づけること.
血管機能のサポートと炎症の軽減における NO 放出カテーターの有効性を評価する.

主な方法:

タニック酸 (TA) とセレノシスタミン (SeCA) を使用したナノコーティングが開発されました.
表面の特徴とNO生成運動を分析した.
細胞活性 (HCASMCs) と炎症反応 (マクロファージ) を in vitro 試験で評価した.

主要な成果:

最適なNO生成は1:4のTA:SeCAモラー比で達成された.
コーティングされたキャセターは72時間以上で96%のHCASMCの活性を維持し,内生的なNOの産生を増加させた.
7 × 10−10 mol cm−2 min−1 の持続的なNO放出が少なくとも3日間観察された.
マクロファージの炎症誘発性サイトカイン (TNF-α,IL-6) の減少

結論:

TA/SeCAナノコーティングは,カテーテルからNOを放出するための堅牢で簡素化された方法を提供します.
コーティングされたキャセターは血管機能の強化と炎症の緩和の可能性を示しています.

キーワード:

S-ニトロスグルタチオンカテーテル窒素酸化物セレノシスタミンタニン酸

さらに関連する動画

High-throughput Identification of Bacteria Repellent Polymers for Medical Devices

High-throughput Identification of Bacteria Repellent Polymers for Medical Devices

Published on: November 5, 2016

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

関連する概念動画

Nitric Oxide Signaling Pathway

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...